ClinicalTrials.gg
RecruitingNCT07509307AMAZE 6Updated Aug 17, 2026

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Obesity, Overweight and Osteoarthritis, Knee, sponsored by Novo Nordisk A/S. Recruiting at 81 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
9th of 24
400 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2028-08
later than 7 of 19 live
Registered
10th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 9th largest by planned enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 7 of the 19 other live ones, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity
  • Overweight
  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female (sex at birth)
  • Age 18 years or above at the time of signing the
  • Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence [KL] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg
  • Symptomatic knee OA with first appearance of pain in the target knee > 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days
  • Willingness to complete a 72-hour of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)/day is allowed as rescue medication up until 24 hours before those visits)

Key Exclusion Criteria:

  • (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening
  • Any joint prosthesis or joint replacement in target knee
  • Arthroscopy or injections into target knee within the last 90 days prior to screening
  • Any other joint disease in target knee including gout and pseudogout
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111

    Participants will be randomized to receive 1 of the 2 dose levels of NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Placebo (matched to NNC0487-0111)

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to NNC0487-0111)

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage change in body weight.

    Time frame: From baseline (week 0) to week 80

  2. Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score

    WOMAC is a participant reported outcome (PRO) measures symptoms in the areas of pain, stiffness, and physical function in participants with osteoarthritis of the hip and/or knee. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis-related disability. Subscale score for pain ranges 0-100, where higher score indicates worse pain. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

Secondary outcomes

  1. Change in WOMAC physical function score

    WOMAC is a PRO measures symptoms in the areas of pain, stiffness, and physical function in participants with osteoarthritis of the hip and/or knee. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis-related disability. Subscale score for physical function ranges 0-100, where higher score indicates worse physical function. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

  2. Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score

    SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate better functional health and well-being. The physical functioning ranges from 19.0 to 57.6. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

  3. Change in body weight

    Measured as kilograms (kg).

    Time frame: From baseline (week 0) to week 80

  4. Change in body mass index (BMI)

    Measured as kilograms per meter squared (kg/m\^2).

    Time frame: From baseline (week 0) to week 80

  5. Change in WOMAC stiffness score

    WOMAC is a PRO measures symptoms in the areas of pain, stiffness, and physical function in participants with osteoarthritis of the hip and/or knee. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis-related disability. Subscale score for stiffness ranges 0-100, where higher score indicates worse stiffness. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

  6. Change in WOMAC total score

    WOMAC is a PRO measures symptoms in the areas of pain, stiffness, and physical function in participants with osteoarthritis of the hip and/or knee. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis-related disability. Total score ranges 0-100, where higher score indicates worse pain, stiffness, physical function and overall osteoarthritis related disability. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

  7. Change in waist circumference

    Measured as centimetres (cm).

    Time frame: From baseline (week 0) to week 80

  8. Change in systolic blood pressure (SBP)

    Measured as millimetre of mercury (mmHg).

    Time frame: From baseline (week 0) to week 80

  9. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to week 80

  10. Ratio to baseline: change in total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  11. Ratio to baseline: change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  12. Ratio to baseline: change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  13. Ratio to baseline: change in very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  14. Ratio to baseline: change in non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  15. Ratio to baseline: change in triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  16. Ratio to baseline: change in high-sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  17. Change in glycated haemoglobin (HbA1c)

    Measured as percentage of HbA1c.

    Time frame: From baseline (week 0) to week 80

  18. Change in fasting plasma glucose (FPG)

    Measured as millimole per litre (mmol/L).

    Time frame: From baseline (week 0) to week 80

  19. Number of participants with use of allowed rescue analgesics during washout period (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  20. Amount of allowed rescue analgesics used during washout period

    Measured as dose of analgesics.

    Time frame: From baseline (week 0) to week 80

  21. Number of participants with use of pain medication (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  22. Amount of pain medication used

    Measured as dose of pain medication.

    Time frame: From baseline (week 0) to week 80

  23. Number of participants with change in pain medication (decrease/no change/increase)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  24. Change in knee pain intensity score (NRS)

    NRS item is PRO measures knee pain at its worst. The measure consists of 1 item. The response scale is an 11-point numeric rating scale from 0 (No knee pain) to 10 (Worst possible knee pain). Higher scores indicate worse pain. Measured as score on a scale.

    Time frame: From baseline (week 0) to week 80

  25. Number of treatment emergent adverse events (TEAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84

  26. Number of treatment emergent serious adverse events (TESAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84

  27. Number of TEAEs leading to permanent treatment discontinuation

    Measured as events.

    Time frame: From baseline (week 0) to week 84

07

Study locations

74 of 81 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 27 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2026
First posted
Apr 3, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Aug 14, 2028
CompletionEst.
Aug 14, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509307
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Apr 20, 2026
Primary completion
Aug 14, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion